doi: 10.1038/s41585-019-0185-3
Healthcare Brew reached out to Trumps transition team and the incoming healthcare picks for comment but did not receive responses by publication
Lifestyle sustainability is paramount: establish a detailed eating plan that maintains the calorie deficit achieved during treatment, implement structured exercise at least 34 days weekly (mixing cardio and resistance work), monitor weight weekly, and build accountability through provider check-ins or coaching
Potential benefits of split dosing include reduced GI side effects (lower peak concentration), more consistent appetite suppression throughout the week, and better tolerance at higher doses
It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings
But what is the difference between the two
